Search Results for: Cybin

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, today announced that it will present at the H.C. Wainwright Annual Global Investment Conference. The event is slated to be held virtually on Sept. 13-15, 2021. Greg McKee, chairman and CEO … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright Global Investment Conference”

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, partnered with Visual Capitalist to create a two-part, data-driven content series and graphic that takes a look at how psychedelics have evolved over the last 6,000 years. The second part specifically … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Part 2 in ‘History of Psychedelics’ Content Series”

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, was featured in a recent equity research report. The coverage, initiated by Ladenburg Thalmann & Co. Inc., highlights Tryp Therapeutics’ efforts to reset the treatment of various disorders through the novel dosing of formulations of … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Equity Research Report”

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced it has completed the training of psychotherapists for its upcoming phase 2a clinical trial using synthetic psilocybin in combination with psychotherapy for overeating disorders. According to the update, the training was conducted by … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Completes Psychotherapy Training for Upcoming Clinical Trial”

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing psilocybin-based compounds for diseases with unmet medical needs through accelerated regulatory pathways, was recently featured as a sponsored content provider on the Visual Capitalist. In the article, part one of a two-part series titled, “The History of Psychedelics (Part 1 of 2),” Tryp … Continue reading “QualityStocksNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Featured in Visual Capitalist Article”